(2) We leveraged this opportunity to combine these building blocks, generating multimeric siRNAs through strain-promoted azide–alkyne cycloaddition ... In this work, a system consisting of an siRNA ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform. The partnership gives ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license ...

LEAD azide is still prepared by using, in principle, a method first described by Curtius 1. This method involves reacting a soluble inorganic azide, preferably sodium azide, with a soluble lead ...

CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

Late clinical-stage biotech ADARx is working on small interfering RNA, or siRNA, therapeutics, a class of molecules capable of regulating gene expression and protein production. The strategic ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) therapeutics across neuroscience, immunology and oncology. The collaboration ...

Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be ...

Sirius' siRNA platform complements our existing capabilities and expands our therapeutic toolkit, enabling us to develop a broader range of transformative gene-based medicines.” “We are ...